JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Prognostic Value of C-Reactive Protein-to-Lymphocyte Ratio in Combined Immunotherapy and Chemotherapy for Small Cell Lung Cancer

  • 0Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University & Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101149, People's Republic of China.
Journal of Inflammation Research +

|

July 22, 2025

|

July 22, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

The C-reactive protein-to-lymphocyte ratio (CLR) can predict outcomes in small cell lung cancer (SCLC) patients receiving chemoimmunotherapy. A decreased CLR after treatment indicates a better response and prolonged progression-free survival (PFS).

Area Of Science

  • Oncology
  • Immunotherapy
  • Biomarkers

Background

  • Inflammatory markers are increasingly recognized as prognostic indicators in small cell lung cancer (SCLC).
  • The prognostic significance of the dynamic C-reactive protein-to-lymphocyte ratio (CLR) in SCLC patients undergoing chemoimmunotherapy requires further investigation.

Purpose Of The Study

  • To evaluate the prognostic value of the dynamic C-reactive protein-to-lymphocyte ratio (CLR) in patients with SCLC treated with chemoimmunotherapy.
  • To analyze the association between changes in CLR and treatment outcomes, including objective response rate (ORR) and progression-free survival (PFS).

Main Methods

  • Retrospective analysis of 88 SCLC patients treated with chemoimmunotherapy from January 2020 to December 2022.
  • Examination of the correlation between CLR dynamics and prognostic outcomes (ORR, PFS).
  • Utilized logistic regression and Kaplan-Meier analyses to assess associations.

Main Results

  • A decrease in CLR was significantly associated with higher ORR (OR=3.91, P<0.05) and prolonged PFS (P=0.02).
  • Multivariate analysis confirmed decreased CLR as a predictor of improved ORR (OR=3.19, P<0.05).
  • An elevated post-treatment CLR (>2.47) correlated with poorer survival outcomes.

Conclusions

  • The dynamic C-reactive protein-to-lymphocyte ratio (CLR) shows potential as a prognostic biomarker for SCLC patients receiving chemoimmunotherapy.
  • A reduction in CLR post-treatment is linked to enhanced objective response rates and improved progression-free survival.

Keywords: